Oral Budesonide for Active Crohn's Disease
Open Access
- 29 September 1994
- journal article
- clinical trial
- Published by Massachusetts Medical Society in The New England Journal of Medicine
- Vol. 331 (13), 836-841
- https://doi.org/10.1056/nejm199409293311303
Abstract
Corticosteroids are the most efficacious drugs for inducing remission in active Crohn's disease, but their benefits are frequently offset by serious side effects. Budesonide is a corticosteroid with high topical antiinflammatory activity but low systemic activity because of extensive hepatic metabolism. We investigated the efficacy and safety of an oral controlled-ileal-release preparation of budesonide in patients with active Crohn's disease involving the ileum or ileum and proximal colon.Keywords
This publication has 17 references indexed in Scilit:
- A Comparison of Budesonide with Prednisolone for Active Crohn's DiseaseThe New England Journal of Medicine, 1994
- Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel diseaseGastroenterology, 1994
- IBD Epidemiology: Ongoing Issues and New Ideas. The Canadian PerspecitveCanadian Journal of Gastroenterology, 1993
- BudesonideDrugs, 1992
- Pituitary–Adrenal Function during Corticosteroid TherapyThe New England Journal of Medicine, 1992
- The Effect of Long-Term Glucocorticoid Therapy on Pituitary–Adrenal Responses to Exogenous Corticotropin-Releasing HormoneThe New England Journal of Medicine, 1992
- Double blind, placebo controlled trial of metronidazole in Crohn's disease.Gut, 1991
- Sulphasalazine and Prednisone Compared with Sulphasalazine for Treating Active Crohn DiseaseAnnals of Internal Medicine, 1991
- Budesonide Enema in Distal Ulcerative Colitis: a Randomized Dose-Response Trial with Prednisolone Enema as Positive ControlScandinavian Journal of Gastroenterology, 1991
- Overview of Newer Glucocorticosteroid Preparations for Inflammatory Bowel DiseaseCanadian Journal of Gastroenterology, 1990